You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Shiga Toxin-Associated Hemolytic Uremic Syndrome: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Adrien JOSEPH.

Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) belongs to the body of thrombotic microangiopathies [1], a heterogeneous group of diseases characterized by a triad of features: thrombocytopenia, mechanical hemolytic anemia with schistocytosis, and ischemic organ damage. It is caused by gastrointestinal infection by a Shiga toxin-producing E. coli (and occasionally other pathogens) and is also called “typical” HUS, as opposed to “atypical” HUS, which results from alternative complement pathway dysregulation, and “secondary” HUS, caused by various co-existing conditions.

  • Shiga toxin
  • Escherichia coli
  • hemolytic uremic syndrome

1. STEC-HUS as a Zoonosis: Reservoirs, Sources, and Modes of Transmission

The importance of cattle as the primary reservoir for STEC has been hypothesized since the first outbreaks associated with undercooked hamburgers [17][1]. Occasionally, sheep [76][2] or goats [77][3] have been reported as sources of outbreaks. Cattle are asymptomatic carriers of STEC: after internalization in bovine epithelial cells, Shiga toxin is excluded from the endoplasmic reticulum and localizes to lysosomes, where its cytotoxicity is abrogated [78][4]. Reported prevalence in farm and slaughterhouse studies varies widely, but a recent meta-analysis yielded an estimated prevalence of E. coli O157:H7 in North America of 10.68% (95% CI: 9.17%–12.28%) in fed beef, 4.65% (95% CI: 3.37%–6.10%) in adult beef, and 1.79% (95% CI: 1.20%–2.48%) in adult dairy. In winter months, the prevalence was nearly 50% lower than that recorded in the summer months [79][5], consistent with the seasonality observed in human infections [80][6]. Contamination by EHEC decreases during processing of the meat [81][7], but some authors reported that salt at concentrations used for this process may in fact enhance Stx production [82][8]. Among animals positive for STEC, the term “super-shedder” is applied to cattle that shed concentrations of E. coli O157:H7 ≥ 10⁴ colony-forming units/g feces. The role of ground beef as a vehicle for STEC seems to be decreasing, and recent outbreaks have been associated with raw milk products, spinach [88][9], municipal drinking water [89][10], or fenugreek [90][11]. In a retrospective analysis of 350 outbreaks in the USA between 1982 and 2002, Rangel and colleagues found that 52% of outbreaks were foodborne (including 21% for which ground beef was the transmission route), 14% resulted from person to person transmission, and 6% from recreational water. The transmission route remained unknown after investigation in 21% of outbreaks [91][12]. It is noteworthy that E. coli can survive for months in the environment, potentially leading to the contamination of fresh produce [92][13].

1.1. Global Burden, Spatial and Temporal Distribution of STEC-HUS Cases

Hemorrhagic colitis and STEC-HUS represent serious health issues, although the global burden remains unclear, chiefly because of the lack of diagnostic tools that are easy to use in routine and a loose surveillance network in many countries. Nonetheless, it has been estimated that STEC accounts for 2.8 million acute illnesses and 3890 HUS cases annually [8][14], with a slight decrease in its incidence since 2000 [8,93][14][15]. The estimated cost of STEC-associated diseases could exceed US$400 million [94,95][16][17]. STEC-HUS is one of the most common diseases requiring emergency renal replacement therapy in children [96][18] and is responsible for 2%–5% of mortality worldwide during the acute phase [97][19]. In global terms, the incidence of STEC-associated diseases varies widely, mainly in relation to environmental and agricultural factors such as stockbreeding, with Argentina having the highest prevalence worldwide: 12.2 cases per 100,000 children younger than 5 years old, approximately 10-fold higher than that in other industrialized countries [8,98,99][14][20][21]. New Zealand reports an annual infection rate of 3.3 per 100,000 persons, whereas neighboring Australia only reports 0.4 cases per 100,000 persons [100][22]. Rural areas also tend to be more affected than urban ones [101,102][23][24], and cases occur predominantly during summer months [99,103][21][25]. Incidence rates of HUS vary greatly depending on the age of the patient and have peaked to 3.3 cases per 100,000 children-years in children aged 6 months to 2 years, for example in France [80][6]. Contrary to common belief, most cases of STEC-HUS are sporadic [99[21][26],104], and the incidence of STEC-HUS has been fairly steady since its recognition in the 1980s, with only a slight decrease after 2000 [8][14], despite public and industry efforts to reduce the risk of food and water contamination [105][27].

1.2. Propensity to Develop STEC-HUS

Approximately 5%–10% of infected patients will develop STEC-HUS about a week after the onset of digestive signs. The propensity to develop the disease varies according to microbiological and individual characteristics, although the determinants of the disease are not fully elucidated. First, the risk of HUS is greater for O157:H7 E. coli (≈10%) and Stx2v-harboring strains than for non-O157 serotypes and Stx1-harboring strains (≈1%) [22,23,41,43,50,62,63][28][29][30][31][32][33][34]. Since the first documented outbreaks in the 1980s, the O157:H7 strain has genetically diversified and concurrently acquired enhanced virulence due to bacteriophage-related insertions, deletions, and duplications [106][35]. Second, age is also an important risk factor for HUS, with peak incidence below 5 years and above 65 years [99,103,107][21][25][36]. Gastric acidity is an important barrier to ingested pathogens, and the use of anti-acid medications has been suggested as a risk factor [93][15]. Behavioral and environmental factors such as eating undercooked meat, contact with farm animals, and consumption of raw milk or well water have been described as risk factors in case control studies [93][15]. Some authors also reported that female sex [108][37] and a higher socio-economic status [109][38] are associated with a higher risk of developing STEC-related disease. Genetic factors, like erythrocyte and serum Gb3 level [110,111][39][40] or presence of the platelet glycoprotein 1b alpha 145M allele [112][41], could also influence the susceptibility to HUS.

2. Pathogenesis

EHEC ranks among the most dreaded enteric pathogens in temperate countries. Following ingestion of contaminated food or water, EHEC displays a sophisticated molecular machinery consisting of a dual strategy: colonization of the bowel and Shiga toxin production. Recent progress in the understanding of HUS mechanisms has highlighted the role of the complement pathway in endothelial damage and gone a long way in deciphering the intracellular trafficking of Shiga toxin. However, most studies have focused on the O157:H7 serotype, and whether the mechanisms uncovered in the setting of O157:H7 infections apply to non-O157 strains, or whether specific mechanisms are involved, is speculative. Another shortcoming has long been the absence of a reliable animal model. Briefly, until recently, murine models did not fully recapitulate the features of STEC-HUS as a result of predominant expression of Gb3 on mouse tubular cells [113][42], as opposed to glomerular endothelial cells in humans [114,115][43][44]. Previous mouse models also relied on the co-injection of lipopolysaccharide (LPS) in order to boost cytotoxicity [116,117,118,119[45][46][47][48][49],120], thus obscuring the significance of the results considering the uncertainty regarding the implication of LPS in this pathology in humans. Indeed, even though the LPS-binding protein has been reported to be elevated in STEC-HUS patients [121][50], the role of endotoxinemia has never been properly demonstrated, as opposed to HUS resulting from Shigellosis [122][51]. More recently, new models have been created with refined Stx2 injection strategies and without the need for LPS injections. These models exhibit a wider range of the pathomechanisms expected in HUS [123][52]. Primate models have sometimes provided conflicting results, as exemplified in Section 4.4 in complement pathway research.

2.1. Colonization of the Bowel: The Attaching and Effacing Phenotype

Prior to adhering to the enterocytes, EHEC must first penetrate the thick mucus layer that protects the enterocytes. It accomplishes this by secreting the StcE metalloprotease, which reduces the inner mucus layer, thus allowing EHEC to access the intestinal epithelium [124][53]. Like the enteropathogenic pathovar [20][54], typical EHEC harbor the LEE [125][55], which includes the type 3 secretion system, a protein appendage capable of translocating a wide repertoire of effector proteins into the cytoplasm of the target cell in the distal ileum. Among these, the translocated intimin receptor (Tir), once injected into the host cell, allows for the attachment of the bacterium. Once expressed on the surface of the enterocyte it acts as the receptor for intimin (eae) and consolidates the attachment of E. coli to mucosal surfaces initiated by their flagella [126][56] and pili [127][57]. Stx plays a role in reinforcing E. coli adherence to the epithelium by increasing the expression of nucleolin, another surface receptor for intimin [128][58]. Tir also links the extracellular bacterium to the cytoskeleton of the host cell via a Tir-cytoskeleton coupling protein (Tccp, also known as EspF(U)), in the presence of a host protein insulin receptor substrate protein of 53 kDa (IRSp53) [129][59], in a process termed “pedestal formation”. Tccp, in turn, activates the actin nucleation-promoting factor WASP/N-WASP, enabling E. coli to literally seize control of the eukaryotic cytoskeletal machinery [130,131][60][61]. However, EHEC are not tissue invasive and, if it was not due to Shiga toxins, their pathological effect would be identical to enteropathogenic E. coli (i.e., invasion of the colon, disruption of tight junctions, and effacement of microvilli, resulting in watery diarrhea) [20][54].

2.2. Shiga Toxin Production and Effect: Gb3 Fixation and Trafficking

After bacterial lysis, Shiga toxins are released into the intestinal lumen, and its B subunit binds to its receptor globotriaosylceramide (Gb3) (see Section 2.2). Normal enterocytes (at variance with colon cancer cells [132][62]) do not express Gb3. Thus, it is believed that Stx translocates across the intestinal epithelium tight junction by binding to Gb3 expressed on Paneth cells, which are seated in the deep crypts of the small intestine [133][63]. Stx does so either by paracellular transport during neutrophil (PMN) transmigration, or by Gb3-independent transcytosis and macropinocytosis [134,135][64][65] before being released into the bloodstream. The mechanisms governing the circulation of Stx from the intestines to the target organs are still debated (reviewed in [136][66]). Some authors point to the role of polymorphonuclear leucocytes as potential carriers [137[67][68],138], but these results have yet to be replicated [139[69][70],140], and Stx possibly only binds to mature polymorphonuclear cells [141][71]. In any case, the estimated half-life of Stx in serum is less than 5 min, as it rapidly diffuses to affected tissues [142][72]. It is thus likely that by the time patients develop HUS, Stx has disappeared from the serum [140,143][70][73]. Expression of Gb3 in humans is restricted to podocytes, microvascular endothelial cells (the highest content being found on microvascular glomeruli) [144[74][75],145], platelets [146][76], germinal center B lymphocytes [147][77], erythrocytes (where it constitutes the rare Pk antigen), and neurons [148][78]. The physiological role of this glycosphingolipid and the reasons behind its specific distribution in human tissues are unknown. A Gb3 knock-out mouse model resulted in no apparent phenotype, except for the loss of sensitivity to Shiga toxins [149][79]. In Gb3-positive cells, the Stx-Gb3 complex induces membrane invagination [150][80] that facilitates endocytosis. Importantly, this initial process of Stx endocytosis is highly dependent on the close connection of Gb3 and lipid rafts [151][81] stemming from animal cell membranes. Indeed, lipid rafts contain caveolin where polymerization provides the platform on which to form early endosomes. The mobilization of microtubular units bring into play both clathrin-dependent [150,152][80][82] and clathrin-independent pathways [153,154][83][84]. Next, the Stx-Gb3 complex is addressed from early endosomes to the endoplasmic reticulum though retrograde transport, making it possible for Stx Gb3 to escape lysosomal degradation [155][85]. During transport [155][85], the catalytic A subunit is cleaved by the protease furin into two fragments: A1 and A2. In the endoplasmic reticulum, the disulfide bound between the two fragments is reduced [156][86], and the A1 fragment translocates into the cytoplasm (anterograde transport) where it is free to exert its cytotoxic effects by removing an adenine base at the N-glycosidic bond from the 28S rRNA of the 60S ribosome [157][87], thus inhibiting protein synthesis leading to cell death [57,158][88][89]. The mechanism allowing Shiga toxins to bypass late endosomes and lysosomes is only partially known, but is thought to involve cycling Golgi protein GPP130, which is susceptible to degradation by physiological concentrations of manganese, yielding hope for a future therapeutic application [159][90]. The pathophysiology of Shiga toxin trafficking and intracellular action is schematized in Figure 31.
Figure 31. Intracellular trafficking and cytotoxicity of Shiga toxin. A simplified depiction of Shiga toxin intracellular trafficking and mechanisms of toxicity. 1: Shiga toxins consist of a monomeric enzymatically active A subunit, non-covalently linked to a pentameric B subunit. The B subunit binds to the glycosphingolipid globotriaosylceramide (Gb3), present in lipid rafts on the surface of the target cell. 2: Shiga toxin and its receptor are internalized (endocytosis), and Shiga toxin is activated through cleavage of the A subunit into 2 fragments by the protease furin (represented by a blue crescent). Disulfide bonds keep the 2 fragments together in the endosome. 3: Shiga toxin avoids the lysosomal pathway and is directed towards the endoplasmic reticulum (retrograde transport) where the disulfide bound is reduced. 4: The A1 subunit translocates into the cytoplasm (anterograde transport) where it can exert its cytotoxic effects. 5: The processed A1 fragment cleaves one adenine residue from the 28S RNA of the 60S ribosomal subunit, thus inhibiting protein synthesis and triggering the ribotoxic and endoplasmic reticulum stress responses. 6: In addition to its ribotoxic effect, Shiga toxin activates multiple stress signaling and apoptotic pathways, and is responsible for the production of inflammatory cytokines by target cells.

2.3. Mechanisms of Shiga Toxin Cytotoxicity

Inhibition of protein translation by ribotoxic stress is the prominent mechanism of Stx cytotoxicity and a major gateway to apoptosis. The processed A1 fragment cleaves one adenine residue from the 28S RNA of the 60S ribosomal subunit, thus inhibiting protein translation and triggering the ribotoxic and endoplasmic reticulum stress responses, which in turn paves the way for cell apoptosis through p38 mitogen-activated protein kinase (p38 MAPK) activation [160,161][91][92] and various apoptotic pathways depending on the infected cell type [162][93]. In addition to its ribotoxic effect, Shiga toxin activates multiple stress signaling and apoptotic pathways, and it is responsible for the production of inflammatory cytokines by target cells. On the cell surface of monocytes, Gb3 surface expression is not associated with lipid rafts, which means that Stx is routed towards the lysosomal pathway [163,164,165][94][95][96]. This results in the production of a high amount of TNF-α, GM-CSF, and IL-8 by monocytes in response to Stx, enhancing endothelial dysfunction and organ damage in patients with HUS [166,167,168,169][97][98][99][100] along a ribotoxic-independent route [170][101]. Stx can also be found in Gb3-negative intestinal cells (probably after internalization by macropinocytosis/transcytosis), where it can modulate the immune response by inhibiting the PI3K/NF-ϰB pathway [171][102].

2.4. Activation of Complement Pathways: Culprit or Innocent Bystander?

By unraveling the role of alternative pathway dysregulation in atypical HUS [172[103][104][105][106][107][108],173,174,175,176,177], investigators have initiated the use of eculizumab, a terminal C5 inhibitor, which is now established as a mainstay in the management of patients with atypical HUS [178,179,180,181,182][109][110][111][112][113]. Evidence has also been garnered suggesting the participation of an alternative pathway in STEC-HUS [183][114]. Plasma levels of Bb and C5b-9, two complement pathway products [184][115], and C3-bearing microparticles from platelets and monocytes [185[116][117],186], were found to be elevated in patients suffering from STEC-HUS. Both decreased at recovery but were not associated with disease severity. Recent in vitro studies demonstrated that Stx is capable of directly activating complement, in addition to its cytotoxic effects. Stx2 binds to complement factor H and its regulators [187,188][118][119]. Furthermore, Stx2 induces the expression of P-selectin on the human microvascular endothelial cell surface, which binds and activates C3 via the alternative pathway, leading to thrombi formation in a murine model of STEC-HUS [189][120]. Recently, serological and genetic complement alterations were reported in 28% of STEC-HUS children [190][121]. Nevertheless, these intriguing results have been diminished by the inability to replicate the findings in nonhuman primate models [191][122]. The absence of C4d or C5b9 by immunochemistry in biopsies from 11 patients during the O104:H4 outbreak is also a source of concern [192][123]. Lastly, mice lacking the lectin-like domain of thrombomodulin, an endothelial glycoprotein with anticoagulant, anti-inflammatory, and cytoprotective properties, show higher glomerular C3 deposits and a higher mortality after intraperitoneal injection of Stx2 + LPS [193][124], and a deficiency of this protein has been implied in rare cases of atypical HUS [194][125]. Although preliminary, these results could provide the rationale for the use of ART-123, a human recombinant thrombomodulin tested in the setting of disseminated intravascular coagulation (without improvement of all-cause mortality) [195][126] and acute exacerbations of idiopathic pulmonary fibrosis (ongoing, NCT02739165), in STEC-HUS. Published results from three patients are encouraging [196][127].

2.5. Endothelial Damage: From Stx Cytotoxicity to Thrombotic Microangiopathy

Once released into the bloodstream, Stx reach target organs [197][128] and bind Gb3 on microvascular endothelial cells. Differences in Gb3 expression distribution across various vascular beds are the basis for differential organ susceptibility to Stx [144,198,199][74][129][130]. Vascular dysfunction is both a hallmark of Shiga toxin pathophysiology and an early harbinger of negative clinical outcomes [200,201][131][132]. Damage to the vascular bed can broadly be categorized as (1) direct cytotoxicity to the endothelium; (2) disturbance of the hemostatic pathway; (3) enhanced release of chemokines; and (4) alternative pathway activation [198,201][129][132]. Shiga toxins induce a profound remodeling of the gene expression repertoire of endothelial cells rather than prompting cell death, provided that vascular cells are subjected to sublethal concentrations of Shiga toxin [199,202][130][133]. The net effect is that endothelial cells adopt a prothrombogenic phenotype by expressing increased levels of tissue factor (TF) [203][134], releasing augmented levels of von Willebrand factor [204[135][136],205], and activating platelets [206][137] via the CXCR4/CXCR7/SDF-1 pathway [202][133]. In addition, Stx stimulates the expression of adhesion molecules [207][138] and inflammatory chemokines [208][139], thereby potentiating the cytotoxity of Stx [209][140] and promoting the adhesion of leucocytes to endothelial cells, which in turn exacerbate thrombosis and tissue damage. At higher concentrations, Stx trigger endothelial apoptosis and cell detachment, exposing the subendothelial bed rich with prothrombogenic tissue factor and collagen [209,210,211][140][141][142]. Finally, Stx elicits the formation of C3- and/or C9-coated microvesicles derived from platelets or red blood cells [185,186,212][116][117][143]. Complement fraction C3a is believed to activate microvascular thrombosis by mobilizing P-selectin on the surface of endothelial cells [189][120]. As a result, Stx-mediated changes in the endothelial phenotype result in a prothrombogenic environment, demonstrated by higher median plasma concentrations of prothrombin fragments, tissue plasminogen activator (t-PA), and D-dimer in children in whom STEC-HUS develops, compared to those with uncomplicated infection [200][131].

References

  1. Riley, L.W.; Remis, R.S.; Helgerson, S.D.; McGee, H.B.; Wells, J.G.; Davis, B.R.; Hebert, R.J.; Olcott, E.S.; Johnson, L.M.; Hargrett, N.T.; et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 1983, 308, 681–685.
  2. Ogden, I.D.; Hepburn, N.F.; MacRae, M.; Strachan, N.J.C.; Fenlon, D.R.; Rusbridge, S.M.; Pennington, T.H. Long-term survival of Escherichia coli O157 on pasture following an outbreak associated with sheep at a scout camp. Lett. Appl. Microbiol. 2002, 34, 100–104.
  3. Bielaszewska, M.; Janda, J.; Bláhová, K.; Minaríková, H.; Jíková, E.; Karmali, M.A.; Laubova, J.; Scikulova, J.; Preston, M.A.; Khakhria, R.; et al. Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat’s milk. Epidemiol. Infect. 1997, 119, 299–305.
  4. Hoey, D.E.E.; Sharp, L.; Currie, C.; Lingwood, C.A.; Gally, D.L.; Smith, D.G.E. Verotoxin 1 binding to intestinal crypt epithelial cells results in localization to lysosomes and abrogation of toxicity. Cell Microbiol. 2003, 5, 85–97.
  5. Ekong, P.S.; Sanderson, M.W.; Cernicchiaro, N. Prevalence and concentration of Escherichia coli O157 in different seasons and cattle types processed in North America: A systematic review and meta-analysis of published research. Prev. Vet. Med. 2015, 121, 74–85.
  6. Bruyand, M.; Mariani-Kurkdjian, P.; Hello, S.L.; King, L.-A.; Cauteren, D.V.; Lefevre, S.; Gouali, M.; Silva, N.J.-D.; Mailles, A.; Donguy, M.-P.; et al. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016. Eurosurveillance 2019, 24.
  7. Elder, R.O.; Keen, J.E.; Siragusa, G.R.; Barkocy-Gallagher, G.A.; Koohmaraie, M.; Laegreid, W.W. Correlation of enterohemorrhagic Escherichia coli O157 prevalence in feces, hides, and carcasses of beef cattle during processing. Proc. Natl. Acad. Sci. USA 2000, 97, 2999–3003.
  8. Harris, S.M.; Yue, W.-F.; Olsen, S.A.; Hu, J.; Means, W.J.; McCormick, R.J.; Du, M.; Zhu, M.-J. Salt at concentrations relevant to meat processing enhances Shiga toxin 2 production in Escherichia coli O157:H7. Int. J. Food Microbiol. 2012, 159, 186–192.
  9. Centers for Disease Control and Prevention (CDC). Importance of culture confirmation of shiga toxin-producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis—New York and North Carolina, 2005. MMWR Morb. Mortal. Wkly. Rep. 2006, 55, 1042–1045.
  10. Salvadori, M.I.; Sontrop, J.M.; Garg, A.X.; Moist, L.M.; Suri, R.S.; Clark, W.F. Factors that led to the Walkerton tragedy. Kidney Int. Suppl. 2009, S33–S34.
  11. Buchholz, U.; Bernard, H.; Werber, D.; Böhmer, M.M.; Remschmidt, C.; Wilking, H.; Deleré, Y.; an der Heiden, M.; Adlhoch, C.; Dreesman, J.; et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N. Engl. J. Med. 2011, 365, 1763–1770.
  12. Rangel, J.M.; Sparling, P.H.; Crowe, C.; Griffin, P.M.; Swerdlow, D.L. Epidemiology of Escherichia coli O157:H7 Outbreaks, United States, 1982–2002. Emerg. Infect. Dis. 2005, 11, 603–609.
  13. Park, S.; Szonyi, B.; Gautam, R.; Nightingale, K.; Anciso, J.; Ivanek, R. Risk Factors for Microbial Contamination in Fruits and Vegetables at the Preharvest Level: A Systematic Review. J. Food Prot. 2012, 75, 2055–2081.
  14. Majowicz, S.E.; Scallan, E.; Jones-Bitton, A.; Sargeant, J.M.; Stapleton, J.; Angulo, F.J.; Yeung, D.H.; Kirk, M.D. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: A systematic review and knowledge synthesis. Foodborne Pathog. Dis. 2014, 11, 447–455.
  15. Rivas, M.; Chinen, I.; Miliwebsky, E.; Masana, M. Risk Factors for Shiga Toxin-Producing Escherichia coli-Associated Human Diseases. Microbiol. Spectr. 2014, 2.
  16. Frenzen, P.D.; Drake, A.; Angulo, F.J. Emerging Infections Program FoodNet Working Group. Economic cost of illness due to Escherichia coli O157 infections in the United States. J. Food Prot. 2005, 68, 2623–2630.
  17. Buzby, J.C.; Roberts, T. The economics of enteric infections: Human foodborne disease costs. Gastroenterology 2009, 136, 1851–1862.
  18. Williams, D.M.; Sreedhar, S.S.; Mickell, J.J.; Chan, J.C.M. Acute kidney failure: A pediatric experience over 20 years. Arch. Pediatr. Adolesc. Med. 2002, 156, 893–900.
  19. Thorpe, C.M. Shiga toxin-producing Escherichia coli infection. Clin. Infect. Dis. 2004, 38, 1298–1303.
  20. Rivas, M.; Miliwebsky, E.; Chinen, I.; Roldán, C.D.; Balbi, L.; García, B.; Fiorilli, G.; Sosa-Estani, S.; Kincaid, J.; Rangel, J.; et al. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog. Dis. 2006, 3, 88–96.
  21. Elliott, E.J.; Robins-Browne, R.M.; O’Loughlin, E.V.; Bennett-Wood, V.; Bourke, J.; Henning, P.; Hogg, G.G.; Knight, J.; Powell, H.; Redmond, D.; et al. Nationwide study of haemolytic uraemic syndrome: Clinical, microbiological, and epidemiological features. Arch. Dis. Child. 2001, 85, 125–131.
  22. Vally, H.; Hall, G.; Dyda, A.; Raupach, J.; Knope, K.; Combs, B.; Desmarchelier, P. Epidemiology of Shiga toxin producing Escherichia coli in Australia, 2000–2010. BMC Public Health 2012, 12, 63.
  23. Karmali, M.A.; Mascarenhas, M.; Petric, M.; Dutil, L.; Rahn, K.; Ludwig, K.; Arbus, G.S.; Michel, P.; Sherman, P.M.; Wilson, J.; et al. Age-Specific Frequencies of Antibodies to Escherichia coli Verocytotoxins (Shiga Toxins) 1 and 2 among Urban and Rural Populations in Southern Ontario. J. Infect. Dis. 2003, 188, 1724–1729.
  24. Kistemann, T.; Zimmer, S.; Vågsholm, I.; Andersson, Y. GIS-supported investigation of human EHEC and cattle VTEC O157 infections in Sweden: Geographical distribution, spatial variation and possible risk factors. Epidemiol. Infect. 2004, 132, 495–505.
  25. Griffin, P.M.; Tauxe, R.V. The Epidemiology of Infections Caused by Escherichia coli O157: H7, Other Enterohemorrhagic, E. coli, and the Associated Hemolytic Uremic Syndrome. Epidemiol. Rev. 1991, 13, 60–98.
  26. Nielsen, E.M.; Scheutz, F.; Torpdahl, M. Continuous Surveillance of Shiga Toxin–Producing Escherichia coli Infections by Pulsed-Field Gel Electrophoresis Shows That Most Infections Are Sporadic. Foodborne Pathog. Dis. 2006, 3, 81–87.
  27. Grisaru, S.; Midgley, J.P.; Hamiwka, L.A.; Wade, A.W.; Samuel, S.M. Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience. Paediatr. Child Health 2011, 16, 337–340.
  28. Boerlin, P.; McEwen, S.A.; Boerlin-Petzold, F.; Wilson, J.B.; Johnson, R.P.; Gyles, C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 1999, 37, 497–503.
  29. Byrne, L.; Vanstone, G.L.; Perry, N.T.; Launders, N.; Adak, G.K.; Godbole, G.; Grant, K.A.; Smith, R.; Jenkins, C. Epidemiology and microbiology of Shiga toxin-producing Escherichia coli other than serogroup O157 in England, 2009–2013. J. Med. Microbiol. 2014, 63, 1181–1188.
  30. Gould, L.H.; Mody, R.K.; Ong, K.L.; Clogher, P.; Cronquist, A.B.; Garman, K.N.; Lathrop, S.; Medus, C.; Spina, N.L.; Webb, T.H.; et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: Epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog. Dis. 2013, 10, 453–460.
  31. Hedican, E.B.; Medus, C.; Besser, J.M.; Juni, B.A.; Koziol, B.; Taylor, C.; Smith, K.E. Characteristics of O157 versus Non-O157 Shiga Toxin-Producing Escherichia coli Infections in Minnesota, 2000–2006. Clin. Infect. Dis. 2009, 49, 358–364.
  32. Hadler, J.L.; Clogher, P.; Hurd, S.; Phan, Q.; Mandour, M.; Bemis, K.; Marcus, R. Ten-Year Trends and Risk Factors for Non-O157 Shiga Toxin–Producing Escherichia coli Found Through Shiga Toxin Testing, Connecticut, 2000–2009. Clin. Infect. Dis. 2011, 53, 269–276.
  33. Ostroff, S.M.; Tarr, P.I.; Neill, M.A.; Lewis, J.H.; Hargrett-Bean, N.; Kobayashi, J.M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 1989, 160, 994–998.
  34. Matussek, A.; Einemo, I.-M.; Jogenfors, A.; Löfdahl, S.; Löfgren, S. Shiga Toxin-Producing Escherichia coli in Diarrheal Stool of Swedish Children: Evaluation of Polymerase Chain Reaction Screening and Duration of Shiga Toxin Shedding. J. Pediatr. Infect. Dis. Soc. 2016, 5, 147–151.
  35. Manning, S.D.; Motiwala, A.S.; Springman, A.C.; Qi, W.; Lacher, D.W.; Ouellette, L.M.; Mladonicky, J.M.; Somsel, P.; Rudrik, J.T.; Dietrich, S.E.; et al. Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc. Natl. Acad. Sci. USA 2008, 105, 4868–4873.
  36. Dundas, S.; Todd, W.T.; Stewart, A.I.; Murdoch, P.S.; Chaudhuri, A.K.; Hutchinson, S.J. The central Scotland Escherichia coli O157:H7 outbreak: Risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001, 33, 923–931.
  37. Gould, L.H.; Demma, L.; Jones, T.F.; Hurd, S.; Vugia, D.J.; Smith, K.; Shiferaw, B.; Segler, S.; Palmer, A.; Zansky, S.; et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin. Infect. Dis. 2009, 49, 1480–1485.
  38. Whitney, B.M.; Mainero, C.; Humes, E.; Hurd, S.; Niccolai, L.; Hadler, J.L. Socioeconomic Status and Foodborne Pathogens in Connecticut, USA, 2000–2011(1). Emerg. Infect. Dis. 2015, 21, 1617–1624.
  39. Newburg, D.S.; Chaturvedi, P.; Lopez, E.L.; Devoto, S.; Fayad, A.; Cleary, T.G. Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J. Infect. Dis. 1993, 168, 476–479.
  40. Watarai, S.; Yokota, K.; Kishimoto, T.; Kanadani, T.; Taketa, K.; Oguma, K. Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera. J. Clin. Microbiol. 2001, 39, 798–800.
  41. Taranta, A.; Gianviti, A.; Palma, A.; De Luca, V.; Mannucci, L.; Procaccino, M.A.; Ghiggeri, G.M.; Caridi, G.; Fruci, D.; Ferracuti, S.; et al. Genetic risk factors in typical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 2009, 24, 1851–1857.
  42. Fujii, Y.; Numata, S.; Nakamura, Y.; Honda, T.; Furukawa, K.; Urano, T.; Wiels, J.; Uchikawa, M.; Ozaki, N.; Matsuo, S.; et al. Murine glycosyltransferases responsible for the expression of globo-series glycolipids: cDNA structures, mRNA expression, and distribution of their products. Glycobiology 2005, 15, 1257–1267.
  43. Argyle, J.C.; Hogg, R.J.; Pysher, T.J.; Silva, F.G.; Siegler, R.L. A clinicopathological study of 24 children with hemolytic uremic syndrome. Pediatr. Nephrol. 1990, 4, 52–58.
  44. Inward, C.D.; Howie, A.J.; Fitzpatrick, M.M.; Rafaat, F.; Milford, D.V.; Taylor, C.M. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr. Nephrol. 1997, 11, 556–559.
  45. Keepers, T.R.; Psotka, M.A.; Gross, L.K.; Obrig, T.G. A Murine Model of HUS: Shiga Toxin with Lipopolysaccharide Mimics the Renal Damage and Physiologic Response of Human Disease. J. Am. Soc. Nephrol. 2006, 17, 3404–3414.
  46. Keepers, T.R.; Gross, L.K.; Obrig, T.G. Monocyte Chemoattractant Protein 1, Macrophage Inflammatory Protein 1α, and RANTES Recruit Macrophages to the Kidney in a Mouse Model of Hemolytic-Uremic Syndrome. Infect. Immun. 2007, 75, 1229–1236.
  47. Roche, J.K.; Keepers, T.R.; Gross, L.K.; Seaner, R.M.; Obrig, T.G. CXCL1/KC and CXCL2/MIP-2 Are Critical Effectors and Potential Targets for Therapy of Escherichia coli O157:H7-Associated Renal Inflammation. Am. J. Pathol. 2007, 170, 526–537.
  48. Mayer, C.L.; Leibowitz, C.S.; Kurosawa, S.; Stearns-Kurosawa, D.J. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins 2012, 4, 1261–1287.
  49. Mohawk, K.L.; O’Brien, A.D. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J. Biomed. Biotechnol. 2011, 2011, 258185.
  50. Proulx, F.; Seidman, E.; Mariscalco, M.M.; Lee, K.; Caroll, S. Increased Circulating Levels of Lipopolysaccharide Binding Protein in Children with Escherichia coli O157:H7 Hemorrhagic Colitis and Hemolytic Uremic Syndrome. Clin. Diagn. Lab. Immunol. 1999, 6, 773.
  51. Koster, F.; Levin, J.; Walker, L.; Tung, K.S.; Gilman, R.H.; Rahaman, M.M.; Majid, M.A.; Islam, S.; Williams, J.R. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Engl. J. Med. 1978, 298, 927–933.
  52. Dennhardt, S.; Pirschel, W.; Wissuwa, B.; Daniel, C.; Gunzer, F.; Lindig, S.; Medyukhina, A.; Kiehntopf, M.; Rudolph, W.W.; Zipfel, P.F.; et al. Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease. Front. Immunol. 2018, 9.
  53. Hews, C.L.; Tran, S.-L.; Wegmann, U.; Brett, B.; Walsham, A.D.S.; Kavanaugh, D.; Ward, N.J.; Juge, N.; Schüller, S. The StcE metalloprotease of enterohaemorrhagic Escherichia coli reduces the inner mucus layer and promotes adherence to human colonic epithelium ex vivo. Cell. Microbiol. 2017, 19.
  54. Croxen, M.A.; Finlay, B.B. Molecular mechanisms of Escherichia coli pathogenicity. Nat. Rev. Microbiol. 2010, 8, 26–38.
  55. McDaniel, T.K.; Jarvis, K.G.; Donnenberg, M.S.; Kaper, J.B. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc. Natl. Acad. Sci. USA 1995, 92, 1664–1668.
  56. Erdem, A.L.; Avelino, F.; Xicohtencatl-Cortes, J.; Girón, J.A. Host Protein Binding and Adhesive Properties of H6 and H7 Flagella of Attaching and Effacing Escherichia coli. J. Bacteriol. 2007, 189, 7426–7435.
  57. Xicohtencatl-Cortes, J.; Monteiro-Neto, V.; Ledesma, M.A.; Jordan, D.M.; Francetic, O.; Kaper, J.B.; Puente, J.L.; Girón, J.A. Intestinal adherence associated with type IV pili of enterohemorrhagic Escherichia coli O157:H7. J. Clin. Investig. 2007, 117, 3519–3529.
  58. Robinson, C.M.; Sinclair, J.F.; Smith, M.J.; O’Brien, A.D. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. USA 2006, 103, 9667–9672.
  59. Weiss, S.M.; Ladwein, M.; Schmidt, D.; Ehinger, J.; Lommel, S.; Städing, K.; Beutling, U.; Disanza, A.; Frank, R.; Jänsch, L.; et al. IRSp53 links the enterohemorrhagic E. coli effectors Tir and EspFU for actin pedestal formation. Cell Host Microbe 2009, 5, 244–258.
  60. Garmendia, J.; Phillips, A.D.; Carlier, M.-F.; Chong, Y.; Schüller, S.; Marches, O.; Dahan, S.; Oswald, E.; Shaw, R.K.; Knutton, S.; et al. TccP is an enterohaemorrhagic Escherichia coli O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton. Cell Microbiol. 2004, 6, 1167–1183.
  61. Cheng, H.-C.; Skehan, B.M.; Campellone, K.G.; Leong, J.M.; Rosen, M.K. Structural mechanism of WASP activation by the enterohaemorrhagic E. coli effector EspF(U). Nature 2008, 454, 1009–1013.
  62. Kovbasnjuk, O.; Mourtazina, R.; Baibakov, B.; Wang, T.; Elowsky, C.; Choti, M.A.; Kane, A.; Donowitz, M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 19087–19092.
  63. Schüller, S.; Heuschkel, R.; Torrente, F.; Kaper, J.B.; Phillips, A.D. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect. 2007, 9, 35–39.
  64. Malyukova, I.; Murray, K.F.; Zhu, C.; Boedeker, E.; Kane, A.; Patterson, K.; Peterson, J.R.; Donowitz, M.; Kovbasnjuk, O. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G78–G92.
  65. Schüller, S. Shiga Toxin Interaction with Human Intestinal Epithelium. Toxins 2011, 3, 626–639.
  66. Brigotti, M. The Interactions of Human Neutrophils with Shiga Toxins and Related Plant Toxins: Danger or Safety? Toxins 2012, 4, 157–190.
  67. Te Loo, D.M.; van Hinsbergh, V.W.; van den Heuvel, L.P.; Monnens, L.A. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. JASN 2001, 12, 800–806.
  68. Brigotti, M.; Caprioli, A.; Tozzi, A.E.; Tazzari, P.L.; Ricci, F.; Conte, R.; Carnicelli, D.; Procaccino, M.A.; Minelli, F.; Ferretti, A.V.S.; et al. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J. Clin. Microbiol. 2006, 44, 313–317.
  69. Geelen, J.M.; van der Velden, T.J.A.M.; Te Loo, D.M.W.M.; Boerman, O.C.; van den Heuvel, L.P.W.J.; Monnens, L.A.H. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol. Dial. Transplant. 2007, 22, 749–755.
  70. Flagler, M.J.; Strasser, J.E.; Chalk, C.L.; Weiss, A.A. Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect. Immun. 2007, 75, 760–765.
  71. Brigotti, M.; Carnicelli, D.; Ravanelli, E.; Barbieri, S.; Ricci, F.; Bontadini, A.; Tozzi, A.E.; Scavia, G.; Caprioli, A.; Tazzari, P.L.; et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J. Leukoc. Biol. 2008, 84, 1019–1027.
  72. Richardson, S.E.; Rotman, T.A.; Jay, V.; Smith, C.R.; Becker, L.E.; Petric, M.; Olivieri, N.F.; Karmali, M.A. Experimental verocytotoxemia in rabbits. Infect. Immun. 1992, 60, 4154–4167.
  73. Brigotti, M.; Tazzari, P.L.; Ravanelli, E.; Carnicelli, D.; Rocchi, L.; Arfilli, V.; Scavia, G.; Minelli, F.; Ricci, F.; Pagliaro, P.; et al. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr. Infect. Dis. J. 2011, 30, 486–490.
  74. Obrig, T.G.; Louise, C.B.; Lingwood, C.A.; Boyd, B.; Barley-Maloney, L.; Daniel, T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 1993, 268, 15484–15488.
  75. Khan, F.; Proulx, F.; Lingwood, C.A. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. Kidney Int. 2009, 75, 1209–1216.
  76. Cooling, L.L.W.; Walker, K.E.; Gille, T.; Koerner, T.A.W. Shiga Toxin Binds Human Platelets via Globotriaosylceramide (Pk Antigen) and a Novel Platelet Glycosphingolipid. Infect. Immun. 1998, 66, 4355–4366.
  77. Mangeney, M.; Richard, Y.; Coulaud, D.; Tursz, T.; Wiels, J. CD77: An antigen of germinal center B cells entering apoptosis. Eur. J. Immunol. 1991, 21, 1131–1140.
  78. Obata, F.; Tohyama, K.; Bonev, A.D.; Kolling, G.L.; Keepers, T.R.; Gross, L.K.; Nelson, M.T.; Sato, S.; Obrig, T.G. Shiga Toxin 2 Affects the Central Nervous System through Receptor Globotriaosylceramide Localized to Neurons. J. Infect. Dis. 2008, 198, 1398–1406.
  79. Okuda, T.; Tokuda, N.; Numata, S.; Ito, M.; Ohta, M.; Kawamura, K.; Wiels, J.; Urano, T.; Tajima, O.; Furukawa, K.; et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 2006, 281, 10230–10235.
  80. Römer, W.; Berland, L.; Chambon, V.; Gaus, K.; Windschiegl, B.; Tenza, D.; Aly, M.R.E.; Fraisier, V.; Florent, J.-C.; Perrais, D.; et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007, 450, 670–675.
  81. Müthing, J.; Schweppe, C.H.; Karch, H.; Friedrich, A.W. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb. Haemost. 2009, 101, 252–264.
  82. Torgersen, M.L.; Lauvrak, S.U.; Sandvig, K. The A-subunit of surface-bound Shiga toxin stimulates clathrin-dependent uptake of the toxin. FEBS J. 2005, 272, 4103–4113.
  83. Villysson, A.; Tontanahal, A.; Karpman, D. Microvesicle Involvement in Shiga Toxin-Associated Infection. Toxins 2017, 9, 376.
  84. Johannes, L.; Parton, R.G.; Bassereau, P.; Mayor, S. Building endocytic pits without clathrin. Nat. Rev. Mol. Cell Biol. 2015, 16, 311–321.
  85. Sandvig, K.; Garred, O.; Prydz, K.; Kozlov, J.V.; Hansen, S.H.; van Deurs, B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992, 358, 510–512.
  86. Garred, O.; Dubinina, E.; Polesskaya, A.; Olsnes, S.; Kozlov, J.; Sandvig, K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J. Biol. Chem. 1997, 272, 11414–11419.
  87. Endo, Y.; Tsurugi, K.; Yutsudo, T.; Takeda, Y.; Ogasawara, T.; Igarashi, K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171, 45–50.
  88. Johannes, L.; Römer, W. Shiga toxins—From cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8, 105–116.
  89. Kavaliauskiene, S.; Dyve Lingelem, A.B.; Skotland, T.; Sandvig, K. Protection against Shiga Toxins. Toxins 2017, 9, 44.
  90. Mukhopadhyay, S.; Linstedt, A.D. Manganese Blocks Intracellular Trafficking of Shiga Toxin and Protects Against Shiga Toxicosis. Science 2012, 335, 332–335.
  91. Cherla, R.P.; Lee, S.Y.; Mees, P.L.; Tesh, V.L. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol. 2006, 79, 397–407.
  92. Jandhyala, D.M.; Ahluwalia, A.; Schimmel, J.J.; Rogers, A.B.; Leong, J.M.; Thorpe, C.M. Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and Contribute to Shiga Toxin-Induced Inflammation. Infect. Immun. 2016, 84, 138–148.
  93. Tesh, V.L. Activation of cell stress response pathways by Shiga toxins. Cell Microbiol. 2011, 14, 1–9.
  94. Van Setten, P.A.; Monnens, L.A.; Verstraten, R.G.; van den Heuvel, L.P.; van Hinsbergh, V.W. Effects of verocytotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996, 88, 174–183.
  95. Ramegowda, B.; Tesh, V.L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 1996, 64, 1173–1180.
  96. Falguières, T.; Mallard, F.; Baron, C.; Hanau, D.; Lingwood, C.; Goud, B.; Salamero, J.; Johannes, L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 2001, 12, 2453–2468.
  97. Eisenhauer, P.B.; Chaturvedi, P.; Fine, R.E.; Ritchie, A.J.; Pober, J.S.; Cleary, T.G.; Newburg, D.S. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect. Immun. 2001, 69, 1889–1894.
  98. Stricklett, P.K.; Hughes, A.K.; Kohan, D.E. Inhibition of p38 mitogen-activated protein kinase ameliorates cytokine up-regulated shigatoxin-1 toxicity in human brain microvascular endothelial cells. J. Infect. Dis. 2005, 191, 461–471.
  99. Stone, M.K.; Kolling, G.L.; Lindner, M.H.; Obrig, T.G. p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells. Infect. Immun. 2008, 76, 1115–1121.
  100. Matussek, A.; Lauber, J.; Bergau, A.; Hansen, W.; Rohde, M.; Dittmar, K.E.J.; Gunzer, M.; Mengel, M.; Gatzlaff, P.; Hartmann, M.; et al. Molecular and functional analysis of Shiga toxin–induced response patterns in human vascular endothelial cells. Blood 2003, 102, 1323–1332.
  101. Lee, M.-S.; Koo, S.; Jeong, D.G.; Tesh, V.L. Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications. Toxins 2016, 8, 77.
  102. Gobert, A.P.; Vareille, M.; Glasser, A.-L.; Hindré, T.; de Sablet, T.; Martin, C. Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J. Immunol. 2007, 178, 8168–8174.
  103. Sellier-Leclerc, A.-L.; Fremeaux-Bacchi, V.; Dragon-Durey, M.-A.; Macher, M.-A.; Niaudet, P.; Guest, G.; Boudailliez, B.; Bouissou, F.; Deschenes, G.; Gie, S.; et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. JASN 2007, 18, 2392–2400.
  104. Noris, M.; Caprioli, J.; Bresin, E.; Mossali, C.; Pianetti, G.; Gamba, S.; Daina, E.; Fenili, C.; Castelletti, F.; Sorosina, A.; et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. CJASN 2010, 5, 1844–1859.
  105. Frémeaux-Bacchi, V.; Miller, E.C.; Liszewski, M.K.; Strain, L.; Blouin, J.; Brown, A.L.; Moghal, N.; Kaplan, B.S.; Weiss, R.A.; Lhotta, K.; et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112, 4948–4952.
  106. Fremeaux-Bacchi, V.; Dragon-Durey, M.-A.; Blouin, J.; Vigneau, C.; Kuypers, D.; Boudailliez, B.; Loirat, C.; Rondeau, E.; Fridman, W.H. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 2004, 41, e84.
  107. De Jorge, E.G.; Harris, C.L.; Esparza-Gordillo, J.; Carreras, L.; Arranz, E.A.; Garrido, C.A.; Lopez-Trascasa, M.; Sanchez-Corral, P.; Morgan, B.P.; de Cordoba, S.R.; et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 2007, 104, 240–245.
  108. Dragon-Durey, M.-A.; Loirat, C.; Cloarec, S.; Macher, M.-A.; Blouin, J.; Nivet, H.; Weiss, L.; Fridman, W.H.; Frémeaux-Bacchi, V. Anti–Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome. J. Am. Soc. Nephrol. 2005, 16, 555–563.
  109. Noris, M.; Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361, 1676–1687.
  110. Fakhouri, F.; Zuber, J.; Frémeaux-Bacchi, V.; Loirat, C. Haemolytic uraemic syndrome. Lancet Lond. Engl. 2017, 390, 681–696.
  111. Legendre, C.M.; Licht, C.; Muus, P.; Greenbaum, L.A.; Babu, S.; Bedrosian, C.; Bingham, C.; Cohen, D.J.; Delmas, Y.; Douglas, K.; et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 368, 2169–2181.
  112. Licht, C.; Greenbaum, L.A.; Muus, P.; Babu, S.; Bedrosian, C.L.; Cohen, D.J.; Delmas, Y.; Douglas, K.; Furman, R.R.; Gaber, O.A.; et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015, 87, 1061–1073.
  113. Fakhouri, F.; Hourmant, M.; Campistol, J.M.; Cataland, S.R.; Espinosa, M.; Gaber, A.O.; Menne, J.; Minetti, E.E.; Provôt, F.; Rondeau, E.; et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am. J. Kidney Dis. 2016, 68, 84–93.
  114. Noris, M.; Mescia, F.; Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 2012, 8, 622–633.
  115. Thurman, J.M.; Marians, R.; Emlen, W.; Wood, S.; Smith, C.; Akana, H.; Holers, V.M.; Lesser, M.; Kline, M.; Hoffman, C.; et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. CJASN 2009, 4, 1920–1924.
  116. Ståhl, A.; Sartz, L.; Karpman, D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011, 117, 5503–5513.
  117. Ge, S.; Hertel, B.; Emden, S.H.; Beneke, J.; Menne, J.; Haller, H.; von Vietinghoff, S. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. Nephrol. Dial. Transplant. 2012, 27, 2768–2775.
  118. Orth, D.; Khan, A.B.; Naim, A.; Grif, K.; Brockmeyer, J.; Karch, H.; Joannidis, M.; Clark, S.J.; Day, A.J.; Fidanzi, S.; et al. Shiga toxin activates complement and binds factor H: Evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 2009, 182, 6394–6400.
  119. Poolpol, K.; Orth-Höller, D.; Speth, C.; Zipfel, P.F.; Skerka, C.; de Córdoba, S.R.; Brockmeyer, J.; Bielaszewska, M.; Würzner, R. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol. Immunol. 2014, 58, 77–84.
  120. Morigi, M.; Galbusera, M.; Gastoldi, S.; Locatelli, M.; Buelli, S.; Pezzotta, A.; Pagani, C.; Noris, M.; Gobbi, M.; Stravalaci, M.; et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 2011, 187, 172–180.
  121. Westra, D.; Volokhina, E.B.; van der Molen, R.G.; van der Velden, T.J.A.M.; Jeronimus-Klaasen, A.; Goertz, J.; Gracchi, V.; Dorresteijn, E.M.; Bouts, A.H.M.; Keijzer-Veen, M.G.; et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr. Nephrol. 2017, 32, 297–309.
  122. Lee, B.C.; Mayer, C.L.; Leibowitz, C.S.; Stearns-Kurosawa, D.J.; Kurosawa, S. Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Blood 2013, 122, 803–806.
  123. Porubsky, S.; Federico, G.; Müthing, J.; Jennemann, R.; Gretz, N.; Büttner, S.; Obermüller, N.; Jung, O.; Hauser, I.A.; Gröne, E.; et al. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J. Pathol. 2014, 234, 120–133.
  124. Zoja, C.; Locatelli, M.; Pagani, C.; Corna, D.; Zanchi, C.; Isermann, B.; Remuzzi, G.; Conway, E.M.; Noris, M. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J. Immunol. 2012, 189, 3661–3668.
  125. Delvaeye, M.; Noris, M.; De Vriese, A.; Esmon, C.T.; Esmon, N.L.; Ferrell, G.; Del-Favero, J.; Plaisance, S.; Claes, B.; Lambrechts, D.; et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361, 345–357.
  126. Vincent, J.L.; Francois, B.; Zabolotskikh, I.; Daga, M.K.; Lascarrou, J.B.; Kirov, M.Y.; Pettilä, V.; Wittebole, X.; Meziani, F.; Mercier, E.; et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA 2019, 321, 1993–2002.
  127. Honda, T.; Ogata, S.; Mineo, E.; Nagamori, Y.; Nakamura, S.; Bando, Y.; Ishii, M. A novel strategy for hemolytic uremic syndrome: Successful treatment with thrombomodulin α. Pediatrics 2013, 131, e928–e933.
  128. Hughes, A.K.; Ergonul, Z.; Stricklett, P.K.; Kohan, D.E. Molecular Basis for High Renal Cell Sensitivity to the Cytotoxic Effects of Shigatoxin-1: Upregulation of Globotriaosylceramide Expression. J. Am. Soc. Nephrol. 2002, 13, 2239–2245.
  129. Zoja, C.; Buelli, S.; Morigi, M. Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. Pediatr. Nephrol. 2010, 25, 2231–2240.
  130. Petruzziello-Pellegrini, T.N.; Moslemi-Naeini, M.; Marsden, P.A. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence 2013, 4, 556–563.
  131. Chandler, W.L.; Jelacic, S.; Boster, D.R.; Ciol, M.A.; Williams, G.D.; Watkins, S.L.; Igarashi, T.; Tarr, P.I. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N. Engl. J. Med. 2002, 346, 23–32.
  132. Goldberg, R.J.; Nakagawa, T.; Johnson, R.J.; Thurman, J.M. The role of endothelial cell injury in thrombotic microangiopathy. Am. J. Kidney Dis. 2010, 56, 1168–1174.
  133. Petruzziello-Pellegrini, T.N.; Yuen, D.A.; Page, A.V.; Patel, S.; Soltyk, A.M.; Matouk, C.C.; Wong, D.K.; Turgeon, P.J.; Fish, J.E.; Ho, J.J.D.; et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J. Clin. Investig. 2012, 122, 759–776.
  134. Nestoridi, E.; Tsukurov, O.; Kushak, R.I.; Ingelfinger, J.R.; Grabowski, E.F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: Implications for the pathophysiology of hemolytic uremic syndrome*. J. Thromb. Haemost. 2005, 3, 752–762.
  135. Huang, J.; Haberichter, S.L.; Sadler, J.E. The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner. Blood 2012, 120, 1143–1149.
  136. Liu, F.; Huang, J.; Sadler, J.E. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood 2011, 118, 3392–3398.
  137. Karpman, D.; Papadopoulou, D.; Nilsson, K.; Sjögren, A.C.; Mikaelsson, C.; Lethagen, S. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001, 97, 3100–3108.
  138. Morigi, M.; Micheletti, G.; Figliuzzi, M.; Imberti, B.; Karmali, M.A.; Remuzzi, A.; Remuzzi, G.; Zoja, C. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 1995, 86, 4553–4558.
  139. Zoja, C.; Angioletti, S.; Donadelli, R.; Zanchi, C.; Tomasoni, S.; Binda, E.; Imberti, B.; te Loo, M.; Monnens, L.; Remuzzi, G.; et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002, 62, 846–856.
  140. Pijpers, A.H.; van Setten, P.A.; van den Heuvel, L.P.; Assmann, K.J.; Dijkman, H.B.; Pennings, A.H.; Monnens, L.A.; van Hinsbergh, V.W. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J. Am. Soc. Nephrol. JASN 2001, 12, 767–778.
  141. Karpman, D.; Håkansson, A.; Perez, M.T.; Isaksson, C.; Carlemalm, E.; Caprioli, A.; Svanborg, C. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: In vivo and in vitro studies. Infect. Immun. 1998, 66, 636–644.
  142. Owens, A.P.; Mackman, N. Tissue factor and thrombosis: The clot starts here. Thromb. Haemost. 2010, 104, 432–439.
  143. Arvidsson, I.; Ståhl, A.-L.; Hedström, M.M.; Kristoffersson, A.-C.; Rylander, C.; Westman, J.S.; Storry, J.R.; Olsson, M.L.; Karpman, D. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J. Immunol. 2015, 194, 2309–2318.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback